FANCC anticorps (AA 61-160) (Cy5)

N° du produit ABIN1704563

Détail du produit anti-FANCC anticorps (Cy5)

Antigène: FANCC (Fanconi Anemia, Complementation Group C (FANCC))

Épitope: AA 61-160

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FANCC est conjugé à/à la Cy5

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Humain

Homologie: Mouse,Rat,Dog,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human FANCC

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur FANCC

Antigène: FANCC (Fanconi Anemia, Complementation Group C (FANCC))

Autre désignation: FANCC (FANCC Produits)

Synonymes: anticorps zgc:154105, anticorps FANCC, anticorps fa3, anticorps fac, anticorps facc, anticorps FA3, anticorps FAC, anticorps FACC, anticorps BB116513, anticorps Facc, anticorps Fanconi anemia complementation group C, anticorps Fanconi anemia, complementation group C, anticorps Fanconi anemia complementation group C L homeolog, anticorps FANCC, anticorps fancc, anticorps fancc.L, anticorps Fancc

Sujet:

Synonyms: bA80I15.1, FA 3, FA3, FAC, FACC, FANCC, FANCC_HUMAN, Fanconi anemia complementation group C, Fanconi anemia complementation group C protein, Fanconi anemia group C protein, Fanconi pancytopenia type 3, FLJ14675, Protein FACC.

Background: Fanconi anemia (FA) is an autosomal recessive disorder characterized by bone marrow failure, birth defects and chromsomal instability (1,2). The FA Group C complementation group gene encodes the protein FANCC, which is located in both cytoplasmic and nuclear compartments. FANCC is expressed in a cell cycle-dependent manner, with the lowest levels at the G1/S boundary and the highest levels in the M-phase. The FANCC protein interacts with other FA complementation group proteins as well as non-FA proteins (3). A human a spectrin II (designated aSpIIs) acts as a scaffold to enhance interactions between FANCC and FANCA to form a nuclear complex (4,5). Another binding partner of FANCC is the BTB/POZ domain containing protein FAZF, which is a transcriptional repressor (6). In hematopoietic cells expressing mutant FANCC, PKR is constitutively phosphorylated and has increased binding affinity for double-stranded RNA (7,8), which suggests that FANCC indirectly suppresses the activity of PKR. These cells are also apoptotic and are hypersensitive to IFNg and TNFa (8). In addition, FANCC protein is involved in the activation of STAT1 through receptors for at least three hematopoietic growth and survival factors (8).

ID gène: 2176

Pathways: Réparation de l'ADN